To explore the opportunity and potential benefit of targeted therapy for advanced and recurrent ONB, we sequenced the whole exomes of the tumor/normal tissues of the patient in our genetic test laboratory, and identified several significantly mutated cancer genes including EGFR, VEGFR2/KDR, FGFR2, and RET (Table 1). The gene discussed is FGFR2; the disease is neoplasm.